Hansoh BioMedical R&D Company
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Inclusion Criteria: 1. Males or females, aged ≥ 18 years. 2. Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors. 3. Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1. Exclusion Criteria: 1. Participants have received or are receiving the following treatment: 1. Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor T cells). 2. Anti-tumor drugs within 14 days prior to the first dose o…
HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles
The recommended dose from the dose-escalation stage and other potential doses will be further explored